Global Primary Ciliary Dyskinesia Market Size, Status and Forecast 2019-2025

Primary ciliary dyskinesia (PCD), also called immotile ciliary syndrome or Kartagener syndrome, is a rare, ciliopathic, autosomal recessive genetic disorder that causes defects in the action of cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tube, and flagella of sperm cells.
There no standardized effective treatment strategies for the condition. Severe fatal respiratory failure can develop; long-term treatment with macrolides such as clarithromycin, erythromycin and azithromycin has been empirically applied for the treatment of primary ciliary dyskinesia in Japan, though controversial due to the effects of the medications.
In 2018, the global Primary Ciliary Dyskinesia market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Primary Ciliary Dyskinesia status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Ciliary Dyskinesia development in United States, Europe and China.

The key players covered in this study
AstraZeneca
Boehringer Ingelheim
Novartis
Teva
Bayer
Rotech Healthcare
Pfizer
...

Market segment by Type, the product can be split into
Genetic Testing
Electron Microscopy

Market segment by Application, split into
Hospitals & Clinics
Research Centers

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Primary Ciliary Dyskinesia status, future forecast, growth opportunity, key market and key players.
To present the Primary Ciliary Dyskinesia development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Primary Ciliary Dyskinesia are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.